期刊
EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 21, 期 5, 页码 559-570出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737175.2021.1907182
关键词
Brain trauma; neuronal death; damp-mediated microglial activation; peroxynitrite; nutraceuticals
This article discusses the therapeutic potential of drugs that inhibit microglial M1 activation and preferentially promote the M2 phenotype to mitigate the second wave of brain injury, and reviews the literature on nutraceuticals with potential clinical applications.
Introduction A delayed second wave of brain trauma is mediated in large part by microglia that are activated to a pro-inflammatory M1 phenotype by DAMP proteins released by dying neurons. These microglia can promote apoptosis or necrosis in neighboring neurons by producing a range of pro-inflammatory cytokines and the deadly oxidant peroxynitrite. This second wave could therefore be mitigated with agents that blunt the post-traumatic M1 activation of microglia and that preferentially promote a pro-healing M2 phenotype. Areas covered The literature on nutraceuticals that might have clinical potential in this regard. Expert opinion The chief signaling pathway whereby DAMPs promote M1 microglial activation involves activation of toll-like receptor 4 (TLR4), NADPH oxidase, NF-kappaB, and the stress activated kinases JNK and p38. The green tea catechin EGCG can suppress TLR4 expression. Phycocyanobilin can inhibit NOX2-dependent NADPH oxidase, ferulate and melatonin can oppose pro-inflammatory signal modulation by NADPH oxidase-derived oxidants. Long-chain omega-3 fatty acids, the soy isoflavone genistein, the AMPK activator berberine, glucosamine, and ketone bodies can down-regulate NF-kappaB activation. Vitamin D activity can oppose JNK/p38 activation. A sophisticated program of nutraceutical supplementation may have important potential for mitigating the second phase of neuronal death and aiding subsequent healing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据